TIL in 2012, India’s Patent Office issued a compulsory license overriding Bayer Pharma’s patent on the cancer drug Nexavar, allowing an Indian generics firm to locally manufacture and sell the drug for just $175/month instead of Bayer's $5,500/month, making the treatment much more accessible.